Evaluation of chemosensitivity of human bone marrow stromal cells - Differences between common chemotherapeutic drugs

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 347-350

  Schmidmaier, Ralf ^a   Baumann, Philipp ^a   Emmerich, Bertold ^a   Meinhardt, Gerold ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute leukemia; Bone marrow stromal cells; Chemosensitivity; Drug resistance; Multiple myeloma

Indexed keywords

ALKYLATING AGENT; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; GEMCITABINE; MELPHALAN; NUCLEOTIDE DERIVATIVE; TREOSULFAN;

ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL GROWTH; CELL STRAIN NCI H929; CELL STRAIN U937; CELL SURVIVAL; CHEMOSENSITIVITY; DRUG SCREENING; HEMATOPOIESIS; HS 5 CELL; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; STROMA CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW CELLS; BUSULFAN; CELL LINE; CYTARABINE; DEOXYCYTIDINE; DOXORUBICIN; HUMANS; MELPHALAN; MULTIPLE MYELOMA; STROMAL CELLS; U937 CELLS;

EID: 32144458104     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dalton WS: The tumor microenvironment: focus on myeloma. Cancer Treat Rev 29 Suppl 1: 11-9, 2003.
2. Hall BM and Gibson LF: Regulation of lymphoid and myeloid leukemic cell survival: role of stromal cell adhesion molecules. Leuk Lymphoma 45: 35-48, 2004.
3. Hazlehurst LA, Landowski TH and Dalton WS: Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22: 7396-7402, 2003.
4. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B and Meinhardt G: The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104: 1825-1832, 2004.
5. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J, Seeber S and Scheuten ME: Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 42: 99-104, 1998.
6. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhauser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko P, Wolf HH, Schindler AE and Seeber S: Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6: 4209-4216, 2000.
7. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, Welles L, Chow SC, Bhamra R and Chaikin P: Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anti-cancer Drugs 14: 239-246, 2003.
8. Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D and Sage RE: Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 22: 348-352, 1988.
9. Meinhardt G, Dayyani F, Jahrsdorfer B, Baumgart J, Emmerich B and Schmidmaier R: Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 122: 892-899, 2003.
10. Schmidmaier R, Oellerich M, Baumgart J, Emmerich B and Meinhardt G: Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1. Exper Haematol 32: 76-86, 2004.
11. Damiano JS, Hazlehurst LA and Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15: 1232-1239, 2001.
12. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-1667, 1999.